P418: DELE1 LOSS AND DYSFUNCTIONAL INTEGRATED STRESS SIGNALING IN TP53 MUTATED AML IS A NOVEL PATHWAY FOR VENETOCLAX RESISTANCE

• David Sharon,
• Paul Jung,
• Yan Sun,
• Weiguo Feng,
• Ziping Yang,
• Valerie Robinson,
• Diya Mitra,
• Wei Liu,
• Pingping Zheng,
• Tami Uziel,
• Lloyd Lam,
• Mark Minden,
• Jeremy Ross,
• Wellington Mendes,
• Jalaja Potluri,
• Andrew Wei,
• Marina Konopleva,
• Monique Dail,
• Brenda Chyla,
• Pk Epling-Burnette

Affiliations

David Sharon

1 AbbVie Inc, Chicago, United States

Paul Jung

1 AbbVie Inc, Chicago, United States

Yan Sun

1 AbbVie Inc, Chicago, United States

Weiguo Feng

1 AbbVie Inc, Chicago, United States

Ziping Yang

1 AbbVie Inc, Chicago, United States

Valerie Robinson

1 AbbVie Inc, Chicago, United States

Diya Mitra

1 AbbVie Inc, Chicago, United States

Wei Liu

1 AbbVie Inc, Chicago, United States

Pingping Zheng

1 AbbVie Inc, Chicago, United States

Tami Uziel

1 AbbVie Inc, Chicago, United States

Lloyd Lam

1 AbbVie Inc, Chicago, United States

Mark Minden

2 Princess Margaret Cancer Centre, University Health Network, Toronto, Canada

Jeremy Ross

1 AbbVie Inc, Chicago, United States

Wellington Mendes

1 AbbVie Inc, Chicago, United States

Jalaja Potluri

1 AbbVie Inc, Chicago, United States

Andrew Wei

3 Peter MacCallum Cancer Centre, Royal Melbourne Hospital Walter and Eliza Hall Institute of Medical Research and University of Melbourne, Melbourne, Australia

Marina Konopleva

4 The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, United States

Monique Dail

5 Genentech Inc, San Francisco, United States

Brenda Chyla

1 AbbVie Inc, Chicago, United States

Pk Epling-Burnette

1 AbbVie Inc, Chicago, United States